Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Conceptual Study of Daratumumab Intensified Treatment to Eligible Multiple Myeloma New Patients- Cyclophosphamide, Thalidomide, Dexamethasone and Daratumumab Induction, Follow by Daratumumab Consolidation and Maintenance

NCT03792620 is registered in ClinicalTrials.gov with Grupo de Estudos Multicentricos em Onco-Hematologia as lead sponsor.

NCT NCT03792620
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03792620 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Conceptual Study of Daratumumab Intensified Treatment to Eligible Multiple Myeloma New Patients- Cyclophosphamide, Thalidomide, Dexamethasone and Daratumumab Induction, Follow by Daratumumab Consolidation and Maintenance
Lead sponsor
Grupo de Estudos Multicentricos em Onco-Hematologia
Phase
Phase 3
Overall status
Unknown status
Start date
November 20, 2018
Completion date
April 30, 2022
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma stage i